Discovery of innovative «first-in-class» therapies, based on the principle of pharmacological chaperones, for the treatment of rare and ultra-rare diseases. 1 ODD (EMA & FDA). Now in Phase II in USA.
2020
Research & development of Biomedical Projects, NMR, Biological & Medical Data Analytics.
2022
Advanced Therapy, CAR-T & Biologics (Antibody Therapy) for solid tumors.